Full-Time
Director – Technical Services/Manufacturing Science
Updated on 7/23/2026
Elanco
5,001-10,000 employees
Global animal health pharmaceutical company
No salary listed
Ames, IA, USA
In Person
Site-based role in Fort Dodge, Iowa; travel approx 10%.
 Biology & Biotech (1) |
|---|
Get referred to Elanco
Find people who can refer or advise you
- Education: Bachelor’s degree in Engineering (Chemical, Mechanical, Bioprocess), Chemistry, Microbiology, or a related scientific or technical discipline.
- Experience: Minimum of 10+ years of experience in pharmaceutical, animal health, or biotechnology manufacturing with progressive leadership in technical services or process engineering.
- Top 2 skills: Deep understanding of Good Manufacturing Practices (GMP) and proven ability to lead and develop high-performing technical teams through complex problem-solving.
- Location: Fort Dodge, IA - Site-Based
- Travel: 10%
Elanco is a global animal health company that develops medicines, vaccines, and preventive care products for livestock and pets. Its products include prescription medicines, vaccines, and parasite-control solutions used by veterinarians, farmers, and pet owners to protect animal health and welfare and improve productivity. After separating from Eli Lilly in 2019, Elanco expanded its scale by acquiring Bayer Animal Health in 2020, which broadened its reach in the companion-animal market and added direct-to-consumer capabilities. Its goal is to advance animal health and welfare worldwide by providing effective, accessible products and services while growing sustainably as a standalone company.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Greenfield, Massachusetts
Founded
1954
Get referred to Elanco
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Befrena's US launch targets the $1.3B dermatology market, potentially displacing incumbent Cytopoint with 6–8 week itch relief.
- Zenrelia achieved blockbuster status with 30% monthly clinic sales growth, driving Elanco's $1.2B innovation revenue target for 2026.
- The AHV acquisition adds Quorum Sensing Technology and StopLac, expanding dairy sustainability solutions and reducing antibiotic use.
What critics are saying
- FDA EUA for generic Nitenpyram from Felix Pharmaceuticals creates a low-cost screwworm alternative, forcing price cuts in 6–12 months.
- PetIQ continues using Seresto's same active ingredients, sustaining direct price pressure in the flea-and-tick collar segment.
- Zoetis's Cytopoint holds 53% clinic share; Befrena must displace this incumbent in a market where payer adoption lags significantly.
What makes Elanco unique
- Elanco uniquely combines veterinary-prescribed products with direct-to-consumer capabilities from its 2020 Bayer Animal Health acquisition.
- Elanco is the only firm shipping a 0.5 mL Lyme-leptospirosis dog vaccine addressing a 40% protection gap in endemic states.
- Elanco leverages PureFil technology to reduce vaccine reactions, a proprietary advantage not offered by competitors like Zoetis.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Hybrid Work Options
401(k) Company Match
Parental Leave
Annual Bonus
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 4%New oral treatment for CKD-related anaemia in cats. 17 Jul 2026 7:00 AM Elanco Animal Health has launched a new treatment to manage feline chronic kidney disease (CKD) anaemia. Varenzin is now available to practices across the UK and offers pet owners "a first-of-its-kind oral suspension that can be administered daily at home". In clinical studies, 68% of cats achieved treatment success after one month. Presented as a once-daily fish oil-flavoured formulation, with "a strong acceptance rate of 88%", the product is designed to stimulate a cat's natural endogenous erythropoietin production (EPO), which is often reduced in cats with kidney disease. The active substance, molidustat, belongs to a novel class of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors and works by activating the body's natural response to low oxygen levels, boosting EPO production and thereby stimulating red blood cell production by the bone marrow, Elanco states.
National Advertising Division finds certain PetIQ claims supported; recommends other comparative claims be modified or discontinued. New York, NY, July 16, 2026 (GLOBE NEWSWIRE) - Following a challenge brought by Elanco Animal Health Incorporated, BBB National Programs' National Advertising Division determined that PetIQ, LLC provided a reasonable basis for its vet-recommended active-ingredient claims for its PetArmor(R) Extend Flea & Tick Collar. However, the National Advertising Division (NAD) recommended that PetIQ modify or discontinue certain claims regarding market leadership, brand growth, consumer trust, comparative performance, and product attributes. PetIQ and Elanco compete in the market for pet flea-and-tick prevention products. Elanco markets Seresto and PetIQ markets PetArmor Extend, which each contain the active ingredients imidacloprid and flumethrin. Elanco challenged PetIQ's brand-superiority and vet-recommended ingredient claims for its PetArmor flea and tick lineup, including assertions that PetArmor Extend is made with the "#1 vet-recommended" active ingredients, alongside claims that PetIQ is the "#1 brand in total solutions" and the "#1 fastest-growing brand" in the category. NAD determined that PetIQ provided a reasonable basis for its vet-recommended active-ingredient claims, finding that PetIQ's survey evidence supported the message that veterinarians recommend the imidacloprid and flumethrin active-ingredient combination more than other flea-and-tick collar active-ingredient combinations. However, NAD determined that PetIQ did not provide adequate support for the broad market-leadership message conveyed by its "#1 Brand in Total Flea & Tick Solutions" claim or the unqualified growth message conveyed by its "#1 Fastest Growing Flea & Tick Brand" claim. Therefore, NAD recommended that the challenged "#1 Brand" and "#1 Fastest Growing" claims be discontinued or modified to avoid conveying unsupported market leadership and growth messages. Additionally, NAD recommended that PetIQ discontinue or modify its challenged "trusted by millions," duration, comparative performance, and product attribute claims to avoid conveying unsupported messages. In its advertiser statement, PetIQ stated it "agrees to comply with its decision." All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes. About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org. About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and creating fair competition for business. Name: Jennifer Rosenberg Email: [email protected] Job Title: Media Relations Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Syngulon announces licensing agreement with Elanco Animal Health. Mar 25, 2026, 11:14 ET SYNGULON SRL, a biotechnology company specializing in genetic technologies for industrial fermentation, and Elanco Animal Health Incorporated, a global leader in animal health, today announced Elanco has obtained a worldwide license to Syngulon's proprietary bacteriocin based microbial selection technologies for use in the development and manufacture of animal health products. CHARLEROI, Belgium, March 25, 2026 /PRNewswire-PRWeb/ - SYNGULON SRL, a biotechnology company specializing in genetic technologies for industrial fermentation, and Elanco Animal Health Incorporated, a global leader in animal health, today announced Elanco has obtained a worldwide license to Syngulon's proprietary bacteriocin based microbial selection technologies for use in the development and manufacture of animal health products. The licensed technology enhances microbial stability and efficiency in industrial fermentation processes, supporting the production of recombinant proteins and plasmid DNA. This collaboration aligns with Elanco's science-based approach to delivering transformative innovations that address unmet customer needs. "We are pleased to collaborate with Elanco, a global leader in animal health, to enable broader application of our antibiotic-free fermentation technologies," said Guy Hélin, Chief Executive Officer of Syngulon. "This non-exclusive agreement validates the strength of our platform and supports our mission to provide innovative, sustainable solutions." "We are excited to work with Syngulon," said Mayur Patel, DVM, MVSc, MBA, Vice President, Global Research & Development at Elanco Animal Health. "Their bacteriocin-based technology represents an important advancement in microbial fermentation and supports our commitment to consistently deliver high-impact innovative solutions for animal health." Both companies emphasized their shared commitment to innovation, responsible biotechnology, and the development of next-generation animal health products. About Syngulon SYNGULON SRL is a biotechnology company based in Belgium focused on the development of proprietary genetic technologies that improve microbial stability and performance in industrial fermentation. Syngulon's platforms enable antibiotic-free selection systems designed to increase efficiency, sustainability, and regulatory acceptability in biomanufacturing. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, Rossitermarketing is committed to breaking boundaries and going beyond to help its customers improve the health of animals in their care, while also making a meaningful impact on its local and global communities. At Elanco, Rossitermarketing is driven by its vision of Food and Companionship Enriching Life and its purpose - all to Go Beyond for Animals, Customers, Society and Its People. Learn more at www.elanco.com. Media Contact SOURCE SYNGULON
ImmuCell appoints former Elanco Animal Health Board member Kathy Turner to Board. PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcare and animal health markets and previously served on the Board of Directors of Elanco Animal Health, a leading animal health company. From 2014 to 2023, she held senior leadership roles at IDEXX Laboratories, including most recently serving as Chief Marketing Officer and Senior Vice President of International Operations, where she contributed to sustained double-digit growth across international markets. Prior to that, Ms. Turner spent nearly 30 years at Abbott Laboratories, where she held multiple leadership roles in global commercial operations. She currently serves on the Board of Veterinarians Without Borders. Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell, commented, "Kathy brings deep experience across the global animal health industry, including her service on the Board of Elanco Animal Health and her leadership in scaling international businesses at IDEXX and Abbott. Her perspective will strengthen our Board as we pursue opportunities to extend the reach of First Defense(R) in the U.S. and internationally." Ms. Turner said, "I am excited to join the Board of ImmuCell. Its hyperimmune colostrum technology and First Defense(R) product line are a compelling platform with meaningful opportunities for growth, and I look forward to supporting the team as it works to expand the reach of its calf health innovations across global animal health markets." The Company sincerely thanks Mr. Rosgen for his many valuable contributions during 8 years of dedicated service. About ImmuCell: ImmuCell Corporation (Nasdaq: ICCC) is an animal health biologics company serving the dairy and beef industries with practical, science-based solutions that improve the survivability, health, and long-term performance of dairy and beef calves. The Company's primary product line, First Defense(R), provides Immediate Immunity(TM) through orally delivered antibodies against the principal viral and bacterial causes of scours, one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at http://www.immucell.com. | Contacts: | Olivier te Boekhorst, President and CEO Timothy C. Fiori, Chief Financial Officer ImmuCell Corporation [email protected] | | / | Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC [email protected] | | / | / |
Elanco Animal (ELAN) climbs 7.6% on upbeat outlook, sets sights on AI. Published on march 18, 2026 at 2:45 am by angelica ballesteros in news. Elanco Animal Health rallied for a third consecutive day on Tuesday, jumping 7.61 percent to finish at $25.18 apiece, as investors took heart from its upbeat outlook for the year, to be supported by plans to leverage AI. At the 2026 KeyBanc Capital Markets Healthcare Forum on the same day, Elanco Animal Health Inc. (NYSE:ELAN) Chief Finance Officer Robert VanHimbergen outlined the company's growth strategy for this year, including plans to grow its organic revenues by 4 to 6 percent and its adjusted EBITDA by 8 percent. He said that the company is planning to take advantage of the rapidly growing AI across various operations and pursue mergers and acquisitions to enhance research and development. The outlook came despite Elanco Animal Health Inc.'s (NYSE:ELAN) dismal earnings performance last year, having swung to a net loss of $232 million from a $338 million net income last year. Revenues, on the other hand, increased by 6 percent to $4.7 billion from $4.44 billion year-on-year. In the fourth quarter alone, net loss widened by 3,350 percent to $276 million from $8 million in the same period a year earlier, while revenues jumped by 12 percent to $1.144 billion from $1.02 billion year-on-year. While we acknowledge the risk and potential of ELAN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ELAN and that has 10,000% upside potential, check out our report about this cheapest AI stock.